Yanqiao Zhang

List of Publications by Year
in descending order

46 papers	4,042 citations	218677 26 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	5135 citing authors

#	Article	IF	Citations
1	Mechanism of the switch from NO to H2O2 in endothelium-dependent vasodilation in diabetes. Basic Research in Cardiology, 2022, 117, 2.	5.9	11
2	Hepatocyte-specific expression of human carboxylesterase 2 attenuates nonalcoholic steatohepatitis in mice. American Journal of Physiology - Renal Physiology, 2021, 320, G166-G174.	3.4	15
3	Hepatocyte Nuclear Factor 4Î± Prevents the Steatosisâ€toâ€NASH Progression by Regulating p53 and Bile Acid Signaling (in mice). Hepatology, 2021, 73, 2251-2265.	7.3	40
4	Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism. Nature Metabolism, 2021, 3, 59-74.	11.9	34
5	Adipocyteâ€specific Loss of Retinoic Acid Receptor Alpha (RarÎ±) Exacerbates Dietâ€induced Obesity and Steatohepatitis in Mice. FASEB Journal, 2021, 35, .	0.5	0
6	Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease. Molecular Metabolism, 2021, 51, 101244.	6.5	35
7	Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis via Hepatocyte Nuclear Factor 4Î±. Diabetes, 2021, 70, 2506-2517.	0.6	8
8	Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis. Molecular Therapy, 2020, 28, 202-216.	8.2	75
9	Hepatocyteâ€Specific Expression of Human Carboxylesterase 1 Attenuates Dietâ€Induced Steatohepatitis and Hyperlipidemia in Mice. Hepatology Communications, 2020, 4, 527-539.	4.3	13
10	Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1574-1587.	2.4	27
11	Lipocalinâ€2 Protects Against Dietâ€Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes. Hepatology Communications, 2019, 3, 763-775.	4.3	22
12	Identification of a novel function of hepatic long-chain acyl-CoA synthetase-1 (ACSL1) in bile acid synthesis and its regulation by bile acid-activated farnesoid X receptor. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 358-371.	2.4	11
13	Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Molecular Metabolism, 2018, 9, 131-140.	6.5	85
14	Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2448-2459.	2.4	19
15	Hepatic Knockdown of Splicing Regulator Slu7 Ameliorates Inflammation and Attenuates Liver Injury in Ethanol-Fed Mice. American Journal of Pathology, 2018, 188, 1807-1819.	3.8	9
16	Implications for Growth Differentiation Factor â€“ 11 in Cardiovascular Disease and Metabolic Syndrome. FASEB Journal, 2018, 32, lb311.	0.5	0
17	Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists. European Journal of Medicinal Chemistry, 2017, 129, 303-309.	5.5	15
18	Activating transcription factor 3 in immune response and metabolic regulation. Liver Research, 2017, 1, 96-102.	1.4	51

#	Article	IF	Citations
19	Hairy and enhancer of split 6 prevents hepatic lipid accumulation through inhibition of Pparg2 expression. Hepatology Communications, 2017, 1, 1085-1098.	4.3	6
20	Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr â^'/â^' mice. Scientific Reports, 2017, 7, 17845.	3.3	19
21	Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. Journal of Clinical Investigation, 2017, 127, 4449-4461.	8.2	127
22	Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emer ging Role of Lipin-1. Current Molecular Pharmacology, 2017, 10, 226-236.	1.5	22
23	Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. Hepatology, 2016, 63, 1860-1874.	7.3	97
24	Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology, 2016, 64, 1072-1085.	7.3	121
25	Carboxylesterase 1 Is Regulated by Hepatocyte Nuclear Factor 4Î± and Protects Against Alcohol- and MCD diet-induced Liver Injury. Scientific Reports, 2016, 6, 24277.	3.3	28
26	A metabolic stress-inducible miR-34a-HNF4Î± pathway regulates lipid and lipoprotein metabolism. Nature Communications, 2015, 6, 7466.	12.8	198
27	A naturally derived dextranâ€"peptide vector for microRNA antagomir delivery. RSC Advances, 2015, 5, 28019-28022.	3.6	8
28	Integrated zwitterionic conjugated poly(carboxybetaine thiophene) as a new biomaterial platform. Chemical Science, 2015, 6, 782-788.	7.4	42
29	Hepatic Carboxylesterase 1 Is Induced by Glucose and Regulates Postprandial Glucose Levels. PLoS ONE, 2014, 9, e109663.	2.5	21
30	Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology, 2014, 59, 1761-1771.	7.3	104
31	Bile acid receptors in non-alcoholic fatty liver disease. Biochemical Pharmacology, 2013, 86, 1517-1524.	4.4	111
32	Loss of FXR Protects against Diet-Induced Obesity and Accelerates Liver Carcinogenesis in ob/ob Mice. Molecular Endocrinology, 2012, 26, 272-280.	3.7	108
33	Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21. Journal of Biological Chemistry, 2012, 287, 25123-25138.	3.4	129
34	Hepatic Hepatocyte Nuclear Factor 4Î± Is Essential for Maintaining Triglyceride and Cholesterol Homeostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 328-336.	2.4	128
35	Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis. Journal of Lipid Research, 2011, 52, 1561-1568.	4.2	40
36	Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia. Journal of Biological Chemistry, 2010, 285, 3035-3043.	3.4	96

#	Article	IF	Citations
37	Farnesoid X receptor: Acting through bile acids to treat metabolic disorders. Drugs of the Future, 2010, 35, 635.	0.1	9
38	FXR signaling in metabolic disease. FEBS Letters, 2008, 582, 10-18.	2.8	178
39	FXR, a multipurpose nuclear receptor. Trends in Biochemical Sciences, 2006, 31, 572-580.	7.5	294
40	FXR Deficiency Causes Reduced Atherosclerosis in Ldlr â^'/â^' Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2316-2321.	2.4	153
41	Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1006-1011.	7.1	806
42	Starvation and Feeding a High-Carbohydrate, Low-Fat Diet Regulate the Expression Sterol Regulatory Element-Binding Protein-1 in Chickens. Journal of Nutrition, 2004, 134, 2205-2210.	2.9	21
43	Peroxisome proliferator-activated receptor-Â coactivator 1Â (PGC-1Â) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes and Development, 2004, 18, 157-169.	5.9	311
44	Syndecan-1 Expression Is Regulated in an Isoform-specific Manner by the Farnesoid-X Receptor. Journal of Biological Chemistry, 2003, 278, 20420-20428.	3.4	77
45	SREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCÎ± transcription in hepatocytes. Journal of Lipid Research, 2003, 44, 356-368.	4.2	82
46	Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional Activation. Journal of Biological Chemistry, 2003, 278, 104-110.	3.4	236